Frontlight ResearchEarly access
Not yet taking people in FrancePhase 1/2
SAR447998 in adults with lupus or rheumatoid arthritis that has not responded to treatment
Tests SAR447998 in adults with lupus or rheumatoid arthritis not helped by other treatments.
Key facts
- Who runs it
- Sanofi-Aventis Recherche & Developpement
- Where
- Marseille, Montpellier Cedex 5, and Pessac, FranceSee the 3 sites
- Trial code
- EU 2026-526117-28-00
- U1111-1342-3194
- Registry title
- Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 10 people, planned
- Started
- 19 Oct 2026
- Expected to end
- 1 Oct 2030
- Type of study
- Interventional
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with refractory systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It tests the safety and early effect of SAR447998.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Refractory systemic lupus erythematosus or rheumatoid arthritis.
Where in France
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceNot yet recruiting
- Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- SAR447998 in adults with lupus or rheumatoid arthritis that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 October 2026